Since the First International Chronic Total Occlusion Summit in 2004, advances in tools and techniques and in patient selection and safety have improved the potential for successful chronic total occlusion (CTO) treatment. This progress is reflected in the live case success rates for the three CTO Summits. Proceedings of TCT 3, 12-14 (2006). view PDF
Tag Archives: cardiovascular system
DES data in high-risk subgroups presented
In addition to addressing the safety and efficacy of drug-eluting stents (DES) in general and relative to one another, randomized controlled trials and registries are now beginning to assess specific lesion subgroups for which DES are not currently approved in the US. These include in-stent restenosis, saphenous vein grafts, bifurcation lesions, left main disease, andContinueContinue reading “DES data in high-risk subgroups presented”
Next generation of DES discussed at Stent Revolution meeting
Several presentations focusing on the safety, efficacy, and appropriate usage of emerging drug-eluting stent technologies were highlighted at the Cardiovascular Research Foundation’s “Enter the Drug-Eluting Stent Revolution V” summit, held in mid March immediately before the annual meeting of the American College of Cardiology. Proceedings of TCT 3, 7-9 (2006). view PDF
Fluent in Science 